Trial · NCT03615326
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR | Global Pembrolizumab + Standard of Care First Course | 10.0 | 95% Confidence Interval 8.6 to 12.2 | Months | |
| Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR | Global Standard of Care | 8.1 | 95% Confidence Interval 7.0 to 8.5 | Months | |
| Overall Survival (OS) | Global Pembrolizumab + Standard of Care First Course | 20.0 | 95% Confidence Interval 17.8 to 22.1 | Months | |
| Overall Survival (OS) | Global Standard of Care First Course | 16.8 | 95% Confidence Interval 14.9 to 18.7 | Months | |
| Objective Response Rate (ORR) Per RECIST 1.1 Assessed by BICR | Global Pembrolizumab + Standard of Care First Course | 72.6 | 95% Confidence Interval 67.6 to 77.2 | Percentage of Participants | |
| Objective Response Rate (ORR) Per RECIST 1.1 Assessed by BICR | Global Standard of Care First Course | 60.1 | 95% Confidence Interval 54.7 to 65.2 | Percentage of Participants | |
| Duration of Response (DOR) Per RECIST 1.1 Assessed by BICR | Global Pembrolizumab + Standard of Care First Course | 11.13 | 95% Confidence Interval 9.8 to 12.7 | Months | |
| Duration of Response (DOR) Per RECIST 1.1 Assessed by BICR | Global Standard of Care First Course | 9.5 | 95% Confidence Interval 7.2 to 11.2 | Months | |
| Number of Participants Who Experienced an Adverse Event (AE) | Global Pembrolizumab + Standard of Care First Course | 348 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Global Standard of Care First Course | 346 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Japan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin | 20 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Japan Trastuzumab + S-1 Plus Oxaliplatin | 20 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AEs | Global Pembrolizumab + Standard of Care First Course | 150 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AEs | Global Standard of Care First Course | 136 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AEs | Japan Pembrolizumab + Trastuzumab + S-1 Plus Oxaliplatin | 11 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AEs | Japan Trastuzumab + S-1 Plus Oxaliplatin | 11 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03615326/results